EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kymera Therapeutics's enterprise value is $1,772.04 Mil.
Kymera Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-143.20 Mil. Therefore, Kymera Therapeutics's EV-to-EBITDA for today is -12.37.
The historical rank and industry rank for Kymera Therapeutics's EV-to-EBITDA or its related term are showing as below:
KYMR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -74.19 Med: -11.62 Max: -2.22
Current: -12.47
During the past 6 years, the highest EV-to-EBITDA of Kymera Therapeutics was -2.22. The lowest was -74.19. And the median was -11.62.
KYMR's EV-to-EBITDA is ranked worse than 100% of 468
companies
in the Biotechnology industry
Industry Median: 9.155
vs KYMR: -12.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Kymera Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Kymera Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kymera Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Kymera Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kymera Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kymera Therapeutics's EV-to-EBITDA falls into.
Kymera Therapeutics's current Enterprise Value is $1,772.04 Mil.
Kymera Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kymera Therapeutics's PE Ratio for today is calculated as:
Kymera Therapeutics's share price for today is $34.98.
Kymera Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Kymera Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Kymera Therapeutics (Kymera Therapeutics) Business Description
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KYMR has been successfully added to your 